| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Medical Oncology [D. S., B. V., L. R., G. T.], Department of Laboratory Medicine [G. D., F. B., M. G.], Hematology [G. A., M. C. T.], and Senology Unit [V. A.], Campus Bio-Medico University, 00155 Rome, and Department of Oncology and Radiotherapy, Azienda Ospedaliera Umberto I, Ancona [C. M., M. T., M. B.], Italy
Purpose: The commercial availability of zoledronic acid, a third generation bisphosphonate, prompted us to evaluate the modifications in angiogenic cytokines levels after a single i.v. infusion of this drug.
Experimental Design: Thirty consecutive cancer patients with scintigraphic and radiographic evidence of bone metastases were treated with a single infusion of 4 mg of zoledronic acid before any chemotherapy. The patients were prospectively evaluated for circulating levels of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) just before and at 1, 2, 7, and 21 days after zoledronic acid infusion.
Results: Basal serum VEGF median levels were significantly decreased at days 2 (-23%), 7 (-28%), and 21 (-34%) after zoledronic acid infusion (P = 0.0498, 0.0090, and 0.0011, respectively). Serum PDGF levels were significantly decreased by 25% 1 day after zoledronic acid infusion (P = 0.0032). This effect on circulating PDGF levels persisted for 2 days after bisphosphonate infusion (P = 0.0050). PDGF levels had returned to values similar to the median basal value at 7 and 21 days. Moreover, a linear regression model with variance analysis showed a significant positive correlation between basal VEGF and PDGF values but not at the following time points. No significant differences were recorded in platelet levels, WBC count, or hemoglobin concentration before and after zoledronic acid single infusion.
Conclusions: This study confirms that zoledronic acid could have an in vivo antiangiogenic property through a significant and long-lasting reduction in serum VEGF levels.
This article has been cited by other articles:
|
|
 |
|
  T. Ibrahim, F. Barbanti, G. Giorgio-Marrano, L. Mercatali, S. Ronconi, C. Vicini, and D. Amadori Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study Oncologist, March 1, 2008; 13(3): 330 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Reid Pathogenesis of Osteonecrosis of the Jaw IBMS BoneKEy, February 1, 2008; 5(2): 69 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Melani, S. Sangaletti, F. M. Barazzetta, Z. Werb, and M. P. Colombo Amino-Biphosphonate Mediated MMP-9 Inhibition Breaks the Tumor-Bone Marrow Axis Responsible for Myeloid-Derived Suppressor Cell Expansion and Macrophage Infiltration in Tumor Stroma Cancer Res., December 1, 2007; 67(23): 11438 - 11446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Scavelli, G. Di Pietro, T. Cirulli, M. Coluccia, A. Boccarelli, T. Giannini, G. Mangialardi, R. Bertieri, A. M. L. Coluccia, D. Ribatti, et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma Mol. Cancer Ther., December 1, 2007; 6(12): 3256 - 3262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Santini, B. Vincenzi, S. Galluzzo, F. Battistoni, L. Rocci, O. Venditti, G. Schiavon, S. Angeletti, F. Uzzalli, M. Caraglia, et al. Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients Clin. Cancer Res., August 1, 2007; 13(15): 4482 - 4486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Roelofs, K. Thompson, S. Gordon, and M. J. Rogers Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res., October 15, 2006; 12(20): 6222s - 6230s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Vessella and E. Corey Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin. Cancer Res., October 15, 2006; 12(20): 6285s - 6290s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Van den Wyngaert, M. T. Huizing, and J. B. Vermorken Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann. Onc., August 1, 2006; 17(8): 1197 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr. Relat. Cancer, March 1, 2006; 13(1): 7 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bamias, E. Kastritis, C. Bamia, L. A. Moulopoulos, I. Melakopoulos, G. Bozas, V. Koutsoukou, D. Gika, A. Anagnostopoulos, C. Papadimitriou, et al. Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors J. Clin. Oncol., December 1, 2005; 23(34): 8580 - 8587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hashimoto, K.-i. Morishige, K. Sawada, M. Tahara, R. Kawagishi, Y. Ikebuchi, M. Sakata, K. Tasaka, and Y. Murata Alendronate Inhibits Intraperitoneal Dissemination in In vivo Ovarian Cancer Model Cancer Res., January 15, 2005; 65(2): 540 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yuasa, M. Nogawa, S. Kimura, A. Yokota, K. Sato, H. Segawa, J. Kuroda, and T. Maekawa A Third-Generation Bisphosphonate, Minodronic Acid (YM529), Augments the Interferon {alpha}/{beta}-Mediated Inhibition of Renal Cell Cancer Cell Growth Both In vitro and In vivo Clin. Cancer Res., January 15, 2005; 11(2): 853 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Avvisati, M. T. Petrucci, O. Annibali, F. Bartolozzi, B. Giannetti, A. Levi, F. Battistoni, M. Gavasci, G. Dicuonzo, B. Vincenzi, et al. Cytokines Behaviour in Multiple Myeloma during Zoledronic Acid Treatment. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 4913 - 4913. [Abstract]
|
|
|
|
|
|
J. R. Green Bisphosphonates: Preclinical Review Oncologist, September 1, 2004; 9(suppl_4): 3 - 13. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
